128 results
8-K
EX-99.1
FGEN
FibroGen Inc
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody
8-K
EX-99.1
FGEN
FibroGen Inc
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, a fully human anti-CTGF
8-K
EX-99.1
96bkuvczdv
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
2gr l6avxe
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
EX-99.1
15klymjkne1rwj kj0od
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
t4721lgw
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
EX-99.1
8lqifwq2qchxalamp
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
EX-99.1
zgw1n8m m5cshen
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
xy8 vys4y7qcesg
7 Nov 22
FibroGen Reports Third Quarter 2022 Financial Results
4:06pm
S-3ASR
ztlcfxumz fkcenhv
8 Aug 22
Automatic shelf registration
5:12pm